Parameter
| Biomarker | Aβ42/40 ratio | Full name | Amyloid-beta 42/40 ratio | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Diagnosis, susceptibility | ||
| Disease | Acute pancreatitis (AP) | Disease Subtypes | / | ||
| Organ | Pancreas | Test Sample / Technology Platform | CSF/plasma (SIMOA, ELISA) | ||
| Pathobiological Mechanisms | Aβ42 aggregates into oligomers and plaques leading to neurotoxicity, while Aβ40 is relatively stable. The reduction of Aβ40 ratio is more reliable than A single indicator to reflect Aβ pathology and indirectly related to the mechanism of pancreatic inflammatory injury | ||||
| Clinical Availability Status | Study validation/early clinical: CSF testing was included in the study criteria; Plasma testing is being validated on a large scale | ||||
| Notes and Dynamics | Plasma Aβ42/40 is A hot spot for early screening and population screening, which is expected to enter clinical practice and provide a supplement for early diagnosis of AP | ||||